Use of the peptide BPC-157, also known as Wolverine, is soaring despite lacking Food and Drug Administration approval

Evolving US policy battles over drug pricing and healthcare affordability, tracking legislation, court rulings, regulatory actions, and industry responses shaping costs, access, and market dynamics.